Tetraphase Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
November 07 2016 - 8:00AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage
biopharmaceutical company developing novel antibiotics to treat
life-threatening multidrug-resistant (MDR) infections, today
announced that company management will give a corporate
presentation at the Stifel 2016 Healthcare Conference on Tuesday,
November 15, 2016 at 3:00 p.m. Eastern Time at the Lotte New York
Palace Hotel in New York City.
A live audio webcast of the Stifel presentation will be
available on the company’s website at
http://ir.tphase.com/events.cfm. An archived presentation
will be available for 30 days.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a clinical-stage biopharmaceutical
company using its proprietary chemistry technology to create novel
antibiotics for serious and life-threatening bacterial infections,
including those caused by many of the multidrug-resistant (MDR)
bacteria highlighted as urgent public health threats by the CDC.
Tetraphase has created more than 3,000 novel tetracycline analogs
using its proprietary technology platform. Tetraphase's
pipeline includes three antibiotic clinical candidates:
eravacycline, which is in phase 3 clinical trials, and TP-271 and
TP-6076, which are in phase 1 clinical trials. Please visit
www.tphase.com for more company information.
Investor Contacts:
Tetraphase Pharmaceuticals
Teri Dahlman
617-600-7040
tdahlman@tphase.com
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com
Media Contact:
Sam Brown Inc.
Mike Beyer
312-961-2502
mikebeyer@sambrown.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024